<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; TRGT</title>
	<atom:link href="http://www.stockbloghub.com/tag/trgt/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AZN) AstraZeneca Sees More Good FDA News</title>
		<link>http://www.stockbloghub.com/2009/12/08/azn-astrazeneca-sees-more-good-fda-news/22203</link>
		<comments>http://www.stockbloghub.com/2009/12/08/azn-astrazeneca-sees-more-good-fda-news/22203#comments</comments>
		<pubDate>Tue, 08 Dec 2009 18:21:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>
		<category><![CDATA[Targacept Inc]]></category>
		<category><![CDATA[TRGT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22203</guid>
		<description><![CDATA[Good news for AstraZeneca (AZN) once again! The company received US Food and Drug Administration (FDA) approval for Seroquel XR (quetiapine fumarate) as an add-on treatment to antidepressants in adults with Major Depressive Disorder (MDD). Seroquel XR is an extended-release version of the company’s currently marketed Seroquel, which is approved for the treatment of bipolar disorder and schizophrenia.The approval comes shortly after AstraZeneca’s announcement of a billion dollar deal with Targacept (TRGT) for the development of a depression drug. However, the company received a complete response letter (CRL) from FDA for Seroquel’s approval as a first-line treatment for MDD. The agency has asked the company to undertake a Risk Evaluation and Mitigation Strategy (REMS) for all approved indications of Seroquel. This requires a proper survey of patients to ensure their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/08/azn-astrazeneca-sees-more-good-fda-news/22203/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) Significant Deal for AstraZeneca</title>
		<link>http://www.stockbloghub.com/2009/12/04/azn-significant-deal-for-astrazeneca/22052</link>
		<comments>http://www.stockbloghub.com/2009/12/04/azn-significant-deal-for-astrazeneca/22052#comments</comments>
		<pubDate>Sat, 05 Dec 2009 01:18:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Targacept Inc]]></category>
		<category><![CDATA[TRGT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22052</guid>
		<description><![CDATA[AstraZeneca (AZN) and Targacept (TRGT) have taken a significant step in the multi-billion dollar antidepressant market. The two companies entered into a collaboration and license agreement regarding the development of a drug targeted towards major depressive disorder (MDD). The drug, TC-5214, Targacept’s late-stage investigational product, recently completed a phase IIb clinical trial. As per terms of the agreement, AstraZeneca will make a $200 million upfront payment to Targacept. In addition, AstraZeneca will pay another $540 million on the achievement of certain regulatory as well as first commercial sale milestones. Terms of the deal are quite attractive for Targacept &#8212; while the company has the potential to receive up to $500 million if some specified sales milestones are achieved, it also has the potential to receive double-digit royalties on net sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/azn-significant-deal-for-astrazeneca/22052/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

